Correspondence 0001193125-23-043242 from Apollomics Inc. (APLM, APLMW) (CIK 0001944885) (APLM)
Apollomics Inc. (APLM, APLMW) (CIK 0001944885)
Date: Feb. 21, 2023 · CIK: 0001944885 · Accession: 0001193125-23-043242
AI Filing Summary & Sentiment
File numbers found in text: 333-268525
Referenced dates: February 17, 2023
Letter
February 21, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street NE
Washington, D.C. 20549
Attn: Tyler Howes
Re: Apollomics Inc.
Amendment No. 3 to Registration Statement on Form F-4
Filed February 10, 2023
File No. 333-268525
Mr. Howes:
On behalf of our client, Apollomics Inc., a Cayman Islands exempted company (the “Company”), we are writing to submit the Company’s responses to the comments of the staff (the “Staff”) of the Division of Corporation Finance of the United States Securities and Exchange Commission (the “SEC”) with respect to the above-referenced Amendment No. 3 to the Registration Statement on Form F-4 filed on February 10, 2023 (File No. 333-268525, the “Registration Statement”), contained in the Staff’s letter dated February 17, 2023 (the “Comment Letter”).
The Company has filed via EDGAR an Amendment No. 4 to the Registration Statement on Form F-4 (“Amendment No. 4”), which reflects the Company’s responses to the comments received by the Staff and certain updated information. For ease of reference, each comment contained in the Comment Letter is printed below in bold and is followed by the Company’s response. All page references in the responses set forth below refer to page numbers in Amendment No. 4. Capitalized terms used but not defined herein have the meanings set forth in Amendment No. 4.
Registration Statement on Form F-4 filed February 10, 2023
Summary of the Proxy Statement/Prospectus
Subscription Agreements, page 36
1. We note that certain accredited investors have entered into subscription agreements to purchase Apollomics Class B Ordinary Shares and Apollomics Series A Preferred Shares in connection with the business combination. Please further highlight the material differences in the terms and price of securities issued at the time of the IPO as compared to private placements contemplated at the time of the business combination. Please also disclose if any of Maxpro’s sponsors, directors, officers or their affiliates will participate in this private placement.
February 21, 2023
Response: In response to the Staff’s comment, the Company has revised the disclosure on the cover of the proxy statement/prospectus and pages 15, 26, 30, 34, 36-37, 135-136, 149, 174, 196-197 and 366-367 of Amendment No. 4.
* * *
Please do not hesitate to contact Daniel Nussen at (213) 620-7796 of White & Case LLP with any questions or comments regarding this letter.
Best regards,
/s/ White & Case LLP
Show Raw Text
CORRESP 1 filename1.htm CORRESP February 21, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street NE Washington, D.C. 20549 Attn: Tyler Howes Re: Apollomics Inc. Amendment No. 3 to Registration Statement on Form F-4 Filed February 10, 2023 File No. 333-268525 Mr. Howes: On behalf of our client, Apollomics Inc., a Cayman Islands exempted company (the “Company”), we are writing to submit the Company’s responses to the comments of the staff (the “Staff”) of the Division of Corporation Finance of the United States Securities and Exchange Commission (the “SEC”) with respect to the above-referenced Amendment No. 3 to the Registration Statement on Form F-4 filed on February 10, 2023 (File No. 333-268525, the “Registration Statement”), contained in the Staff’s letter dated February 17, 2023 (the “Comment Letter”). The Company has filed via EDGAR an Amendment No. 4 to the Registration Statement on Form F-4 (“Amendment No. 4”), which reflects the Company’s responses to the comments received by the Staff and certain updated information. For ease of reference, each comment contained in the Comment Letter is printed below in bold and is followed by the Company’s response. All page references in the responses set forth below refer to page numbers in Amendment No. 4. Capitalized terms used but not defined herein have the meanings set forth in Amendment No. 4. Registration Statement on Form F-4 filed February 10, 2023 Summary of the Proxy Statement/Prospectus Subscription Agreements, page 36 1. We note that certain accredited investors have entered into subscription agreements to purchase Apollomics Class B Ordinary Shares and Apollomics Series A Preferred Shares in connection with the business combination. Please further highlight the material differences in the terms and price of securities issued at the time of the IPO as compared to private placements contemplated at the time of the business combination. Please also disclose if any of Maxpro’s sponsors, directors, officers or their affiliates will participate in this private placement. February 21, 2023 Response: In response to the Staff’s comment, the Company has revised the disclosure on the cover of the proxy statement/prospectus and pages 15, 26, 30, 34, 36-37, 135-136, 149, 174, 196-197 and 366-367 of Amendment No. 4. * * * Please do not hesitate to contact Daniel Nussen at (213) 620-7796 of White & Case LLP with any questions or comments regarding this letter. Best regards, /s/ White & Case LLP cc: Guo-Liang Yu, Apollomics Inc. 2